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Abstract: Hepatocellular carcinoma (HCC) develops on the background of liver cirrhosis often 
from multiple, simultaneous factors. The diagnosis of a single small HCC comes with good 
prognosis and provides a potential for cure. In contrast, the diagnosis of multifocal, large HCC 
has high mortality and poor prognosis. Unfortunately, the majority of HCC is diagnosed at such 
late stages. A surveillance program endorsed by regional liver societies involves six-monthly 
ultrasound surveillance of at-risk patients. This had been in action for the last two decades. It 
has led to marked increase in the proportion of patients presenting with small unifocal nodules 
found on surveillance. The development of tools to enhance our ability in optimizing available 
surveillance is likely to improve the prognosis of patients with HCC. In this review, we discuss 
the difficulties in utilizing HCC surveillance and possible means of improvement.
Keywords: hepatocellular carcinoma, surveillance, screening, risk stratification
Introduction
Hepatocellular carcinoma (HCC) is a global health problem. It is the second most 
common cause of cancer-related mortality and the sixth most common cause of can-
cer worldwide.1 This discrepancy between incidence and mortality emphasizes the 
aggressive nature and poor prognosis of this tumor. HCC has the fastest rising tumor 
incidence in the west.2,3 This is partly related to the rising epidemic of its triggers, such 
as fatty liver, alcohol, and viral hepatitis.
The process of hepatocarcinogenesis starts with one or more triggering factors 
causing inflammation and fibrosis of what was previously a normal liver. As fibrosis 
becomes advanced, the risk of developing cancer gets higher. Eventually with ongoing 
liver cell injury, a focus of dysplasia arises within a genetically and immunologically 
susceptible liver as demonstrated in Figure 1. This may develop into a dysplastic nodule 
and subsequently HCC.
The triggers vary in intensity and in their ability to cause cancer. Hepatitis B 
virus (HBV) is thought to be the most carcinogenic trigger as the DNA of the virus 
integrates with host genome. It is the most common cause of HCC in the East, but 
is rarely seen in the Western world especially with better control of viral replication 
using nucleotide and nucleoside inhibitors. Hepatitis C virus (HCV) remains the most 
common cause of HCC in the Western world. The mechanism by which this RNA 
virus leads to cancer remains largely unknown, but in theory is attributed to chronic 
inflammation caused by the virus. Recent advances in the treatment of HCV using 
directly acting antiviral agents (DAAs) may have large consequences on the landscape 
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of HCC epidemiology. Recently, multiple reports indicating 
unexpectedly non-diminishing and possibly increasing rates 
of HCC occurrence after successful eradication of HCV by 
DAAs had been published.4–7 However, data from the English 
Expanded Access Program showed no increase in liver malig-
nancy post treatment with DAA.8 More evidence regarding 
the risk of HCC in cirrhotic patients with no history of cancer 
and treatment by non-interferon-based therapies is currently 
awaited. Nonalcoholic steatohepatitis (NASH) and alcohol-
related liver injury remain very common causes of HCC in 
the Western hemisphere. They are expected to become the 
most common causes of HCC in the future.
HCC runs an essentially subclinical course (Figure 1). 
Patients tend to present at late stages when symptoms arise 
with subsequent poor prognosis. The known genomic changes 
in early HCC are subtle in comparison to advanced disease. 
This has led to difficulties in discovering novel genomic-
based diagnostic biomarkers.
Who is at risk and should be under 
regular surveillance?
The risk of HCC varies on patient by patient basis. The single 
most important risk factor in the development of HCC is the 
presence of liver cirrhosis. HCC risk increases as more triggers 
are acquired, for example, fatty liver disease, increased alcohol 
intake, or exposure to aflatoxin. Similarly, as age and stage of 
fibrosis advance, the risk increases particularly in males. It is 
difficult to design a one-size-fits-all package for calculating 
risk and therefore the potential need for surveillance because 
the epidemiology relating to potential etiology varies globally. 
Similarly, the threshold for cost effectiveness of screening may 
vary according to the national economic situation.
HCC risk stratification models
Risk stratification models aim to rationalize surveillance deci-
sions according to the predicted risk of developing HCC. The 
majority of risk stratification models have been developed 
using regression analysis of large retrospective cohorts of 
patients who developed HCC. Many of which were developed 
in the context of a unique risk factor, for example, hepatitis 
B or C virus infection.
HCC risk stratification models in 
HBV infection
The initial systems were developed in the East in the context of 
endemic HBV and were focused on this viral etiology alone. 
They gave high weight to HBV DNA levels and were developed 
prior to widespread use of nucleot(s)ide inhibitors. The initial 
two scoring systems, GAG-HCC (Guide with Age, Gender, 
HBV DNA, Core promoter mutations and Cirrhosis)9 and 
CU-HCC (Chinese University-HCC),10 were similar in content. 
These were followed by the REACH-B (Risk Estimation for 
Figure 1 Natural history of HCC demonstrating the journey of a liver as it goes through cirrhosis, dysplasia, carcinoma, and multifocal cancer.
Notes: The parallel symptoms and known genomic features take a much more subtle course at the early stages and intensifies at the late stage.
Abbreviation: HCC, hepatocellular carcinoma.
Symptoms
Genomic
evolution
Normal
Trigger
Cirrhosis Dysplasia
Non-cirrhotic HCC 10–15%
Dysplastic nodule HCC Multifocal HCC
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Hepatocellular Carcinoma in Chronic Hepatitis B) scoring 
system that was developed based on data from 3,584 patients 
included in the Risk Evaluation of Viral Load Elevation and 
Associated Liver Disease/Cancer - Hepatitis B Virus-HBV 
study and validated on a large cohort by the same group.11 They 
were developed using similar methodologies with multivariate 
analysis of possible predictors of development of HCC in large 
retrospective cohorts of HBV patients followed by validation in 
separate cohorts. The three above scores had many similarities, 
including age, gender, and HBV DNA.
More recently, stage of fibrosis measured using noninvasive 
markers had been incorporated into the scoring systems. Tran-
sient elastography (TE) or acoustic radiation frequency index 
has shown promising potential in predicting HCC. The efforts 
started by the modification of the CU-HCC score by the same 
authors to include liver stiffness measurement (LSM) instead 
of subjective ultrasound scan (U/S) interpretation of possible 
cirrhosis.12 Liver stiffness was added to the other variables 
including HBV DNA. Later on, the REACH-B score was 
also modified to include liver stiffness instead of HBV DNA 
for patients achieving complete viral response on therapy.13 A 
study comparing all the above risk stratification systems on 
a large retrospective cohort found the modified REACH-B 
score to be the best predictor of HCC for patients on antiviral 
therapy treated according to guidelines set by the Korean 
Association for the study of the Liver.14 More recently, the 
PAGE-B (platelets, age, gender-HBV) model was specifically 
developed on a large Caucasian population with HBV and on 
either tenofovir or entecavir for >1 year. The model includes 
neither measures of fibrosis nor DNA levels. It simply relies 
on age, gender, and platelets. It showed very high negative 
predictive value.15 Further validation on independent data sets 
is still required. Table 1 summarizes the key components of 
HBV-related HCC risk, stratification systems, and mREAC.
HCC risk stratification in HCV 
infection
There are currently four HCC prediction models developed 
exclusively in the context of HCV infection. The most recent 
model was prospectively developed and validated on a 
French HCV-related compensated cirrhotic cohort of patients 
(n=1,323). The Cox proportional hazards model was used 
to identify factors significantly associated with subsequent 
development of HCC. These included age, past alcohol intake, 
platelet count, gamma-glutamyltransferase, and non-sustained 
virological response during the study period (Table 2). The 
cohort included patients treated by interferon and others 
treated by DAAs. The authors  suggest that after further nec-
essary validation, the model can be utilized to stratify HCV 
cirrhotic patients to high and low risk and prioritize available 
resources for surveillance accordingly. The authors did not 
mention specific cut offs but rather interpretation of the risk 
on nomogram and subsequent decision making is required.16
The earliest model analyzed a cohort of patients with 
advanced fibrosis and previous response failure on treatment 
with interferon (n=1,005) included in the HALT-C (Hepatitis 
C Antiviral Long-Term Treatment against Cirrhosis) clinical 
trial. The Cox proportional hazards model was used to identify 
three continuous variables (age, alkaline phosphatase, and 
platelet count) as well as three categorical variables (black race, 
esophageal varices, and smoking) required to calculate the risk 
of HCC development. A complex equation is used for calcu-
lation (age ×0.049+black race ×0.712+alkaline phosphatase 
×0.006+esophageal varices ×0.777+ever smoked ×0.749+plate-
lets ×−0.011). Interpretation of the results is similarly complex 
(0–log
10
 (1.50), log
10
 (1.50)–log
10
 (3.25), and >log
10
 (3.25) sug-
gest low, intermediate, and high risk, respectively). Lack of easy 
to use online calculators and certainly subsequent validation 
in the last 7 years makes its practical role near out-of-date.17
Table 1 Key components of the recent HBV-related HCC risk 
stratification systems
Criteria mREACH-B LSM-HCC
mCU-HCC
PAGE-B
Age (years) 30–34: 0
35–39: 1
40–44: 2
45–49: 3
50–54: 4
55–59: 5
60–65: 6
<51: 0
>50: 10
16–29: 0
30–39: 2
40–49: 4
50–59: 6
60–69: 8
≥70: 1
Gender Male: 2
Female: 0
NA Female: 0
Male: 6
Albumin, g/L NA <36: 1
>35: 0
NA
Platelets, ×109/L NA NA ≥200,000: 0
100,000–199,999: 6
<100,000: 9
ALT, U/L <15: 0
15–44: 1
>44: 2
NA NA
HBeAg Positive: 2
Negative: 0
NA NA
DNA NA ≤2×105 IU/mL: 0
>2×105 IU/mL: 5
NA
LS (kPa) <8: 0
8–13: 2
>13: 4
<8: 0
8–12: 8
>12: 14
NA
Optimal cut offa 10 11 17
Notes: aOptimal cut-off for predicting HCC development in 5 years.
Abbreviations: ALT, alanine transaminase; HBeAg, hepatitis B viral protein; HCC, 
hepatocellular carcinoma; LS, liver stiffness; LSM, liver stiffness measurement; 
NA, not applicable; mREACH, modified REACH; mCU-HCC- modified Chinese 
University-HCC; PAGE-B, platelets, age, gender-HBV.
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The group from Houston published analysis of data from 
the National Department of Veterans Affairs (VA) includ-
ing 11,721 cirrhotic patients with HCV. The group aimed 
to enhance the performance of alpha-fetoprotein (AFP) as a 
diagnostic biomarker for HCC by incorporating other clinical 
and laboratory data. Serial age, platelet count, alanine trans-
aminase (ALT) as well as the AFP/ALT and AFP/platelet value 
interactions had the highest impact on incorporation with 
serial AFP.18,19 Lack of data on response to HCV treatments 
if any, as well as generalizability to female non-VA cohorts 
maybe considered as setbacks to this approach until further 
validation or updates are available. The algorithm itself is 
complicated and requires web-based software for calculation.
Chang et al recently published data from a large retrospec-
tive cohort of HCV patients from a single center in Taiwan 
(n=1,879) who had previous treatment using interferon-based 
therapies. The included patients were all assessed by liver 
biopsy. Age, male gender, platelet count, AFP, high stage 
fibrosis, HCV genotype 1b, and non-sustained virologic 
response (SVR) were all independent predictors of HCC in 
this study population. Key components and cut off are sum-
marized in Table 2. A cut-off score of 5 had negative and 
positive predictive values of 94.34% and 34.83%, respec-
tively. Generalizability to HCV patients from West treated 
by DAAs cannot be stipulated. Similarly, an assessment of 
the utility of noninvasive markers in replicating the role of 
liver biopsy in this context is still required.20
HCC risk stratification in the 
context of variable risk factors
The largest study (age, diabetes, race, etiology, gender, and 
severity [ADRESS]-HCC) was performed on 34,932 mostly 
decompensated cirrhotic patients from the US national liver 
transplant waiting list. The Cox proportional hazards regres-
sion model was used to identify six predictors of HCC (age, 
diabetes, race, etiology, sex, and severity according to Child–
Turcotte–Pugh score). These were used to construct the model 
and this was followed by internal and external validation. The 
majority of patients (45.7%) were HCV, and other etiologies 
included HBV (2.8%), NASH (17.5%), and alcohol related 
(18.3%). The algorithm is complex and requires electronic 
calculation, it provides the 1-year of developing HCC.21
The Japanese group from Hyogo College of Medicine 
more recently developed a model (virtual touch quantifica-
tion, fasting plasma glucose, male, age, AFP [VFMAP]) for 
all patients with liver disease. This included patients with 
HBV (n=264, 14.6%), HCV (n=635, 35.1%), and non-B 
non-C (n=898, 49.7%). The non-B non-C group included 
modest numbers of nonalcoholic fatty liver disease (n=96, 
5.3%) and alcohol-related liver disease (n=22, 1.2%). The 
etiology of liver disease in the largest group (n=724, 40%) 
was not specified by the authors. The majority of included 
patients (85.2%) were non-cirrhotic. The model includes 
virtual touch quantification (score 0 if <1.33 m/s and 1 if 
>1.33 m/s), fasting plasma glucose (score 0 if <110 mg/dL 
and 1 if >110 mg/dL), age (score 0 if <55 years and 1 if >55 
years), gender (score 0 if female and 1 if male), and AFP 
(score 0 if <5 ng/mL and 1 if >5 ng/mL). It showed a reas-
suringly high negative predictive value (98.2%) using total 
cut-off score of 3. This could be useful in excluding patients 
from surveillance programs when validated.22
Two general population-based HCC prediction models 
were developed in Japan23  and Taiwan24 where HCC is much 
common than in the West.
Clinical guidelines
The most recent European, Asian Pacific, and American 
HCC guidelines recommend that patients at higher risk of 
developing HCC should have regular surveillance.25–27 The 
guidelines currently do not incorporate risk stratification 
models, but this may happen in the future specially after 
further validation of promising models like the modified 
Table 2 Key components of the recent HCV-related HCC risk 
stratification systems
Criteria Ganne-Carrié et al16 Chang et al20 
Age (years) <50: 0
>50: 2
<60: 0
>60: 1
Platelet (×109/L) <100: 3
100–150: 2
>150: 0
<150: 1
>150: 0
SVR Yes: 0
No: 3
Yes: 0
No: 2
Past excessive alcohol Yes: 1
No: 0
NA
GGT >ULN: 2
<ULN: 0
NA
Gender NA Male: 1
Female: 0
AFP (ng/mL) NA >20: 1
<20: 0
Fibrosis (biopsy) modified 
Knodell histology index
NA 0–2: 0
3,4: 2
HCV genotype NA Non-GT1b: 0
GT1b: 2
Optimal cut-off Low <3, high >8
Nomogram required
5
Abbreviations: AFP, alpha-fetoprotein; GGT, gamma-glutamyl transpeptidase; 
HCC, hepatocellular carcinoma; HCV, hepatitis B virus; SVR, sustained virologic 
response; ULN, upper limit of normal; NA, not applicable.
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REACH-B and VFMAP. The guidelines refer to high risk 
groups as all cirrhotic patients and some non-cirrhotics as 
outlined in Table 3. Surveillance may not be feasible in some 
patients at high risk of developing HCC if they are not fit to 
tolerate treatment.
The guidelines specify factors influencing the risk of 
development of HCC in non-cirrhotic individuals to include 
viral hepatitis and family history of HCC; more specifically, 
fibrosis stage F3 and above in the case of HCV as well as 
race, viral replication, and age in the case of HBV.
In summary, predicting HCC is not straightforward. It is a 
malignancy occurring on the background of another disease 
with variable triggers and increasing degrees of severity, 
that is, chronic liver disease. It is thus difficult to create a 
robust and economically feasible one-size-fits-all surveil-
lance model. Risk stratification models are a promising tool 
in identifying patients at higher risk. Prospective validation 
of such models would justify their possible incorporation 
in routine clinical practice. On the basis of our collective 
interpretation of the published HCC risk prediction models, 
the following factors as summarized in Table 4 are potentially 
associated with increased risk.
In the meantime, regional guidance is available as outlined 
above to support clinical decision making. Guidelines con-
sider cost effectiveness based on gain in life expectancy of >3 
months with a cost of <$50,000 per year of life saved.27 This is 
based on evidence from >20 years ago.28 Guidelines indicate 
that an incidence of ≥1.5%/year would warrant surveillance 
of HCC in cirrhotic and 0.2%/year in non-cirrhotic patients. 
The latter however is based on much weaker  evidence. Such 
thresholds are difficult to test and implement due to various 
issues, for example, economical and ethical. Nomogram 
interpretation and subsequent decision making according 
to local economy as recently suggested by the French group 
seem more practical.16
How to screen?
Ultrasound
U/S is currently the only screening test recommended by 
regional liver societies as part of surveillance for HCC.25–27 
This involves firstly identifying a pre-specified patient 
population at relatively high risk of developing cancer and 
inviting them for regular screening with U/S for early detec-
tion of cancer. This can be challenging as not all patients at 
risk are known to be at risk. A study on a large US veteran 
population cohort (n=1,201) with HCC and liver cirrhosis 
found that 24.6% of the patients were not known to have liver 
cirrhosis prior to the diagnosis of HCC. This implies that a 
100% efficient surveillance program will still miss 1 every 4 
new HCCs.29 This however would be over optimistic as meta-
analysis of 9 US-based studies including 17,286 patients 
with liver cirrhosis under regular clinical follow-up (primary, 
secondary, or tertiary) found that 81.6% of the patients were 
not practically engaged with regular surveillance for HCC. 
The study concluded that screening for HCC is under-utilized 
despite being considered as standard of care in the USA.30 
Factors leading to this significant under-utilization possibly 
includes primary care defects, poor patient engagement, 
or logistical issues in test arrangements. A single tertiary 
Table 3 Summary of guideline recommendations on surveillance 
of non-cirrhotic patients
Recommendations for surveillance of non-cirrhotic livers
European Association for study of the liver (EASL)
Hepatitis B virus carriers (HBV)
Adults with family history of HCC (Asian or African)
Adults with active viral replication (Asian or African)
Hepatitis C virus (HCV)
Bridging fibrosis (Metavir F3) and above
American Association for Study of the Liver (AASLD)
HBV carriers
Family history of HCC
African/North American black
Female Asian aged >50 years and male Asian aged >40 years
Uncertain benefit
Asian HBV <40-year-old male or 50-year-old female
HCV with bridging fibrosis (Metavir F3) and above
Noncirrhotic, nonalcoholic fatty liver disease (NAFLD)
Asian Pacific Association for Study of the Liver (APASL)
No recommendations for surveillance of non-cirrhotic population
Abbreviation: HCC, hepatocellular carcinoma.
Table 4 Factors associated with increased risk of HCC based on 
interpretation of recently published risk prediction models
Increased risk of HCC
General risk factors
Age, gender, and family history
Etiology of liver disease
Alcohol and diabetes +/– markers of insulin resistance
AFP
Hepatitis C virus (HCV)
SVR
Modality of treatment (awaits further studies)
Hepatitis B virus (HBV)
DNA replication if any
Non-cirrhotic
Markers of fibrosis
Cirrhotic
Platelet count
Child–Pugh score (if decompensated)
Abbreviations: AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; SVR, 
sustained virologic response.
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 referral center study found that only 5 out of 48 patients under 
regular U/S surveillance for HCC understood the reason for 
having a regular U/S.31 As a result, this implies that a 100% 
efficient screening test will be practically utilized by only 
15% of the patients who need it. In addition, the sensitivity 
of U/S is not 100%. In a meta-analysis of prospective studies 
on 1,514 patients, the pooled sensitivity of U/S was 63%.32 
This relatively low sensitivity has a number of potential 
explanations, as follows:
1. Performer variations and inter-rater reliability.
2. Patient factors including obesity and gaseous distension.
3. Tumor factors including location and echogenicity.
4. Factors related to background liver with a heterogeneous 
pattern in macronodular cirrhosis or severe steatosis.
Despite such difficulties, the widespread use of U/S sur-
veillance appears to have had a large impact on HCC in the 
two decades as summarized in the next section.
Biomarkers
AFP is an alpha-globulin, originally detected in serum of 
a patient with HCC in Russia.33 AFP is typically raised 
in advanced HCC. On meta-analysis, the use of AFP 
alongside U/S scanning increased the sensitivity of HCC 
detection from 63% to 69%.32 The specificity improves 
only on raising cut-off values to levels around 400 ng/
mL. Its incorporation in surveillance programs is not part 
of most current regional liver society guidance.25–27 It is, 
however, still endorsed by national guidance in the UK34 
and Japan.35
More recently, the strength of evidence on the prognostic 
role of AFP is increasing. First, Hoshida et al associated AFP 
with poor prognosis of HCC on transcriptomal analysis.36 
This was followed by Duvoux et al who published a landmark 
study demonstrating that HCC outside Milan criteria will 
have relatively good prognosis if AFP is not elevated and 
vice versa.37 Due to its high impact and clinical relevance, 
this was quickly incorporated into the UK transplant rules 
where AFP >1,000 IU/mL is an absolute contraindication 
for liver transplantation.
The following biomarkers have been tested but none have 
been incorporated into routine clinical practice.
1. Des-gamma-carboxy prothrombin also known as pro-
thrombin induced by vitamin K absence II (PIVKA II)
2. Ratio of glycosylated to total AFP (L3 AFP)
3. Alpha fucosidase
4. Glypican 3
Currently, there are no genomic-based biomarkers 
available for diagnosis of HCC. This could be related to the 
scarcity of genomic alterations in HCC at the early stages 
as outlined in Figure 1. Some promising future markers are 
outlined in the next section.
Screening intervals
The recommended screening interval in the Western world is 
6 months. Some guidelines have recommended screening is 
performed every 3 months specifically for “very high-risk” 
patients, for example, cirrhotic HBV with high viral replica-
tion although the evidence on which this was based is scarce.35 
There is a large patient variability in incidence and volume 
doubling time of HCC and theoretically a 6-month period may 
be too long for some patients to have their HCC detected at 
an early stage. A large multicenter controlled trial in France 
randomized cirrhotic patients to three monthly (n=640, mean 
follow-up of 47 months) or six monthly (n=638, mean follow-
up of 46 months) surveillance for HCC. Three monthly sur-
veillance detected more <10 mm focal lesions that required 
further surveillance. This however led to more investigations 
to follow-up those nodules with no significant overall increase 
in diagnosing HCC in comparison to the six-monthly group. 
There was no difference in survival between both groups. The 
majority of patients (>83%) included in this European study 
were HCV and alcohol-related liver disease.
In summary, a six-monthly interval of screening is 
endorsed the Western world and there is RCT evidence to 
suggest that there is no benefit in more frequent scanning. 
The recall logistics and patient compliance play a major role 
in the actual utilization of surveillance. In the next section 
we review possibilities to improve recall.
Impact of U/S surveillance
In the management of HCC, there is seemingly an implicit 
sharp cutting edge between patients suitable for curative 
therapies at diagnosis and those who are not. Larger multi-
centeric tumors have high rates of recurrence if treated with 
a curative intention. Therefore, the stage of HCC at diagnosis 
is crucial in predicting prognosis.
The impact of surveillance is demonstrated on comparing 
the HCC staging system used in the 80s published by Okuda 
et al38 with the current widely used Barcelona Clinic Liver 
Cancer (BCLC) staging system.39 The Okuda staging system 
evaluated tumor size according to whether it involves more 
or less than 50% of the total volume of the liver in contrast to 
the BCLC published almost three decades later and evaluates 
nodules as little as 2 cm.
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Screening for hepatocellular carcinoma
There is only one large population-based controlled 
trial randomizing patients between no surveillance and 
 surveillance with U/S and AFP. The study was performed on 
18,816 HBV patients from a single village in Shanghai with 
5-year follow-up. Half the patients were randomized to either 
surveillance with U/S and AFP or no surveillance. It showed 
a significant improvement in survival of the patients within 
the surveillance group. HCC mortality rate in the surveillance 
group was 83.2/100K versus 131.5/100K for controls, with a 
mortality rate ratio of 0.63 (95% CI: 0.41–0.98).40
The future of screening and 
surveillance
U/S of high-risk patients remains the recommended modality 
for screening in the absence of reliable biomarkers in HCC 
but this is clearly inadequate with a major need for new 
screening tools. Such developments seem some way off so 
currently the focus will remain on optimizing U/S usage as 
a screening test.
High-risk patients who are not yet diagnosed or identi-
fied as high risk with liver cirrhosis will not be included into 
surveillance programs and, therefore, cannot benefit. This 
means a key strategy for improving cancer detection must be 
to increase the proportion of patients in whom a diagnosis of 
cirrhosis is made. Because previously a diagnosis was only 
able to be made on liver biopsy or on imaging in those with 
advanced liver disease, a high proportion of patients with 
liver cirrhosis will remain undiagnosed in the community. In 
Nottingham, we increased the number of diagnosed compen-
sated cirrhosis in the community by 140% using noninvasive 
measures of fibrosis in asymptomatic but high-risk patients 
and this seems the most likely type of strategy to enhance 
identification and therefore to be able to screen a higher 
proportion of high-risk people.41
Noninvasive measures of fibrosis were recently reviewed 
by Chin et al42 and are objective and easy to perform in pri-
mary care. Similarly, many patients will have routine liver 
function tests (LFTs) performed during primary care visits 
or non-liver-related admissions to hospital. We previously 
published a risk stratification model that would predict 
future liver disease based on a scoring system which includes 
age, gender, LFTs, deprivation status, and alcohol intake.43 
Improved primary care diagnostic pathways of subclinical 
liver cirrhosis has the potential to limit the burden of compli-
cations, not only HCC but also variceal bleeding and others.
To optimize HCC surveillance, physicians need to work 
in close partnership with their patients as there is evidence 
that this will improve compliance and outcome. Better patient 
education by specialist nurses, official education websites, 
patient groups, education screencasts, and smart phone 
applications is part of modernization of patient management 
pathways, replacing noninteractive and static patient leaflets. 
Patient engagement in clinical decision making and an active 
role in deciding whether or not they require HCC surveillance 
are strongly recommended.
Liver cirrhosis can cause multiple complications and 
currently patients may be advised to visit the hospital fre-
quently for investigations and consultations. This may lead to 
poor compliance. One-stop clinics had successful outcomes 
with other specialties, for example, in patients presenting 
with symptoms of heart failure.44 A similar model offering 
educational sessions, clinical consultation, dietician review, 
alcohol liaison service input, U/S, TE, and endoscopy for 
liver patients on the same day may be much more convenient 
for the patient and enhance uptake of screening but there is 
currently no evidence to quantify this.
Investigating new biomarkers of 
HCC
Recent next-generation sequencing (NGS) studies have 
shown that genomic changes in HCC evolve in a stepwise 
fashion paralleling the phenotypic changes.45 There are a 
large number of mutations known to occur in HCC however 
these are mostly detected at a late stage and each occurring 
in relatively low frequencies. Recent NGS studies however 
showed relatively high-frequency TERT mutations in early 
HCC and some dysplastic nodules.46
Living cells frequently shed DNA which circulates 
freely in the plasma. Cancer cells among other living cells 
will do the same. Therefore, a proportion of plasma cell-
free DNA (cfDNA) will harbor specific genomic features 
unique to the tumor, known as circulating tumor DNA 
(ctDNA). Similarly, some whole tumor cells will shed 
into the blood stream and become circulating tumor cells 
(CTCs) both of which provide potential targets as early 
diagnostic tests. Pilot studies have investigated mutations 
in the plasma of patients with HCC. Targeted NGS of 
common HCC mutations (TERT, TP53, and CTNNB1) 
in tumor and plasma-matched DNA of 41 patients were 
performed. Tumor-associated mutations were detectable 
in 19.5% of the plasma samples.47 There is also evidence 
that there is a directly proportional relationship between 
the concentration of ctDNA detected in plasma and cancer 
progression.48 The group from Newcastle has also recently 
optimized methodologies for characterization of CTCs in 
HCC.49 Circulating tumor cells and DNA are an exciting 
new potential and further investigations into their role as 
diagnostic biomarkers is awaited.
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Fateen and Ryder
In summary, this review serves to provide insight into 
issues regarding surveillance of patients at risk of developing 
HCC. Risk stratification and optimization of patient man-
agement pathways have been discussed with focus on tools 
with potential for rapid clinical applicability. Genomic-based 
biomarker research is an exciting future advancement, which 
requires detailed investigations.
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